DeepMed Research

Rogel Cancer Center: University of Michigan

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: -

Market Cap: -

Website: http://www.rogelcancercenter.org

Clinical Trials

Patient-centered Development of the Cancer Support Community's Open to Options ®Chatbot Program

Not Applicable

Terminated

Conditions: Cancer

Interventions: Behavioral: Online Survey
Behavioral: Chatbot prototype
Behavioral: Open to Options (O2O) Program

First Posted Date: 2020-11-05

Last Posted Date: 2022-08-11

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 18

Registration Number: NCT04616651

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications

Not Applicable

Terminated

Conditions: Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Multiple Chronic Conditions

Interventions: Other: Patient Reported Outcome Measure (PROM)
Other: Comprehensive Medication Review (CMR)
Other: Communications between oncology and primary care pharmacists

First Posted Date: 2020-10-22

Last Posted Date: 2022-11-22

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 6

Registration Number: NCT04595851

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma

Phase 2

Recruiting

Conditions: Glioblastoma

Interventions: Radiation: Dose-Intensified Radiotherapy
Drug: Temozolomide
Drug: Adjuvant temozolomide

First Posted Date: 2020-10-05

Last Posted Date: 2025-04-02

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 30

Registration Number: NCT04574856

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors

Early Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: Potato starch

First Posted Date: 2020-09-17

Last Posted Date: 2024-02-28

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 12

Registration Number: NCT04552418

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Surgical Treatment of Post-surgical Mastectomy Pain Utilizing the Regenerative Peripheral Nerve Interface

Not Applicable

Completed

Conditions: Post-Mastectomy Chronic Pain Syndrome

Interventions: Procedure: Regenerative Peripheral Nerve Interface

First Posted Date: 2020-08-28

Last Posted Date: 2023-10-30

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 25

Registration Number: NCT04530526

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

Phase 1

Recruiting

Conditions: Liver Malignancy

Interventions: Drug: Yttrium-90
Device: Selective Internal Radiation Therapy
Radiation: Stereotactic Body Radiation Therapy
Diagnostic Test: PET/CT
Device: Therasphere

First Posted Date: 2020-08-19

Last Posted Date: 2024-11-06

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 65

Registration Number: NCT04518748

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors

Early Phase 1

Completed

Conditions: Neuroendocrine Tumors

Interventions: Drug: 3-[18F]Fluoro-para-hydroxyphenethylguanidine
Diagnostic Test: Positron emission tomography/computed tomography scan
Drug: [123I] metaiodobenzylguanidine
Diagnostic Test: Planar scintigraphy scan
Diagnostic Test: Single photon emission computed tomography/computed tomography scan

First Posted Date: 2020-08-12

Last Posted Date: 2025-01-10

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 32

Registration Number: NCT04510311

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

Phase 3

Terminated

Conditions: Gynecologic Cancer

Interventions: Drug: Ondansetron
Drug: Dexamethasone
Drug: Neurokinin-1 Receptor Antagonist (NK1-RA)
Drug: Olanzapine
Drug: Compazine

First Posted Date: 2020-08-07

Last Posted Date: 2025-02-04

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 62

Registration Number: NCT04503668

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy

Phase 1

Terminated

Conditions: Advanced Adult Hepatocellular Carcinoma

Interventions: Drug: Cabozantinib

First Posted Date: 2020-08-04

Last Posted Date: 2024-08-06

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 3

Registration Number: NCT04497038

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 1 locations

A Pilot Study of Roadmap 2.0 in Oncology Caregivers and Patients

Not Applicable

Completed

Conditions: Cancer
Quality of Life

Interventions: Behavioral: Roadmap 2.0 information system
Other: Wearable activity sensor
Other: Survey administration

First Posted Date: 2020-07-21

Last Posted Date: 2023-11-29

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 138

Registration Number: NCT04480541

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy